HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

Benzinga · 3d ago
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $165 price target.